885068-19-9

Basic information

• Product Name: Carbonic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl 4-nitrophenyl ester
• CAS NO: 885068-19-9
• Molecular Formula: C26H20Cl2N4O6
• Molecular Weight: 555.374
• Mol File: 885068-19-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Carbonic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl 4-nitrophenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbonic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl 4-nitrophenyl ester(885068-19-9)
• EPA Substance Registry System: Carbonic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]phenyl 4-nitrophenyl ester(885068-19-9)

Safety Data

• Hazardous Substances Data: 885068-19-9(Hazardous Substances Data)

Upstream product

• 885066-89-7 3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenol 
• 7693-46-1 4-Nitrophenyl chloroformate 

Relevant articles and documents

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.